R&D News | pharmaphorum

News

FDA approves Bayer/Merck & Co heart failure drug

Bayer and Merck & Co’s heart failure drug vericiguat has been approved by the FDA under the brand name Verquvo, in an increasingly competitive market.

News

Will Gottlieb follow up on Trump's promise of a bonfire of regulations?

Biden appoints veteran Woodcock as interim FDA commissioner

Agency veteran Dr Janet Woodcock is the new interim FDA commissioner appointed by president Joe Biden to replace outgoing Trump appointee Stephen Hahn.

News

Coronavirus vaccine: how pharma is picking up the pace

Pfizer/BioNTech say COVID-19 vaccine works against UK varian...

Laboratory studies have confirmed that antibodies stimulated by Pfizer and BioNTech’s COVID-19 vaccine can neutralise the new, more transmissible variant of SARS-CoV-2 identified in the UK.

News

ConserV Bioscience works on mutation-proof coronavirus shots...

UK biotech ConserV Bioscience has joined with California’s Lawrence Livermore National Laboratory to develop broad-spectrum coronavirus vaccines as concerns mount over potentially more infe

News

J&J single-shot COVID-19 vaccine shows early promise

J&J has announced early trial results that suggest its single-shot coronavirus vaccine provides a sustained response against the virus ahead of a phase 3 trial readout due later this mo

News

Celltrion closes in on COVID-19 antibody market after trial ...

South Korea’s Celltrion has announced encouraging top-line results for its potential antibody therapy for COVID-19, with the first part of a phase 2/3 trial showing it could cut recovery ti

FDA approves Bayer/Merck & Co heart failure drug

Biden appoints veteran Woodcock as interim FDA commissioner

Pfizer/BioNTech say COVID-19 vaccine works against UK varian...

ConserV Bioscience works on mutation-proof coronavirus shots...

J&J single-shot COVID-19 vaccine shows early promise

Celltrion closes in on COVID-19 antibody market after trial ...

Amazon puts $100m into global health drive

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks